275 related articles for article (PubMed ID: 34462786)
41. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I
Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851
[TBL] [Abstract][Full Text] [Related]
42. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
43. Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.
Mikkelsen SU; Kjaer L; Bjørn ME; Knudsen TA; Sørensen AL; Andersen CBL; Bjerrum OW; Brochmann N; Fassi DE; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Pallisgaard N; Thomassen M; Skov V; Hasselbalch HC
Cancer Med; 2018 Aug; 7(8):3571-3581. PubMed ID: 29932310
[TBL] [Abstract][Full Text] [Related]
44. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
45. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Stein BL; Moliterno AR; Tiu RV
Ann Hematol; 2014 Dec; 93(12):1965-76. PubMed ID: 25270596
[TBL] [Abstract][Full Text] [Related]
46. How I treat polycythemia vera.
Passamonti F
Blood; 2012 Jul; 120(2):275-84. PubMed ID: 22611155
[TBL] [Abstract][Full Text] [Related]
47. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
[TBL] [Abstract][Full Text] [Related]
48. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M; Mora B; Ball S; Iurlo A; Elli EM; Finazzi MC; Polverelli N; Rumi E; Caramella M; Carraro MC; D'Adda M; Molteni A; Sissa C; Lunghi F; Vismara A; Ubezio M; Guidetti A; Caberlon S; Anghilieri M; Komrokji R; Cattaneo D; Della Porta MG; Giorgino T; Bertù L; Brociner M; Kuykendall A; Passamonti F
Blood Adv; 2022 Mar; 6(6):1855-1864. PubMed ID: 35130339
[TBL] [Abstract][Full Text] [Related]
49. Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Rastrelli M; Ferrazzi B; Tropea S; Costa A; Finotto S; Marino D; Campana L; Del Fiore P; Rossi CR; Alaibac M
In Vivo; 2019; 33(5):1667-1669. PubMed ID: 31471421
[TBL] [Abstract][Full Text] [Related]
50. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Verstovsek S; Vannucchi AM; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Kirito K; Besses C; Hino M; Moiraghi B; Miller CB; Cazzola M; Rosti V; Blau I; Mesa R; Jones MM; Zhen H; Li J; Francillard N; Habr D; Kiladjian JJ
Haematologica; 2016 Jul; 101(7):821-9. PubMed ID: 27102499
[TBL] [Abstract][Full Text] [Related]
51. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up.
Senín A; Fernández-Rodríguez C; Bellosillo B; Camacho L; Longarón R; Angona A; Besses C; Álvarez-Larrán A
Ann Hematol; 2018 Mar; 97(3):443-451. PubMed ID: 29181548
[TBL] [Abstract][Full Text] [Related]
52. Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis.
Koshiishi M; Sueki Y; Kawashima I; Nakajima K; Mitsumori T; Kirito K
Intern Med; 2017 Sep; 56(17):2335-2338. PubMed ID: 28794380
[TBL] [Abstract][Full Text] [Related]
53. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
54. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract][Full Text] [Related]
55. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F
Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472
[TBL] [Abstract][Full Text] [Related]
56. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
57. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
[TBL] [Abstract][Full Text] [Related]
58. Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report.
Al-Mashdali AF; Kashgary WR; Yassin MA
Medicine (Baltimore); 2021 Nov; 100(44):e27722. PubMed ID: 34871267
[TBL] [Abstract][Full Text] [Related]
59. Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Elli EM; Di Veroli A; Bartoletti D; Iurlo A; Carmosino I; Benevolo G; Abruzzese E; Bonifacio M; Bergamaschi M; Polverelli N; Caramella M; Cilloni D; Tiribelli M; Pugliese N; Caocci G; Crisà E; Porrini R; Markovic U; Renso R; Auteri G; Cattaneo D; Trawinska MM; Scaffidi L; Biale L; Bucelli C; Breccia M; Gambacorti-Passerini C; Palumbo GA; Latagliata R; Palandri F
Br J Haematol; 2022 Apr; 197(2):190-200. PubMed ID: 35137397
[TBL] [Abstract][Full Text] [Related]
60. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]